CS Paper Radar

DrugTargetWorld: A Synthetic Biobank for Training and Benchmarking AI Scientists

Samuel Margolis, Paul Schmiedmayer, Alan Huang, Ethan Chen, Ishan Bhattacharjee, Atman Shah, Ben Viggiano, Fang Cao, Shriya Reddy, Roger Xia, Jack O'Sullivan, Daniel Katz, Matthew Wheeler, Euan Ashley, Bruna Gomes

cs.AI ·submitted 2026-10-07 06:59 UTC · v1
code/data

Abstract

Drug target discovery requires distinguishing molecules that causally drive disease from those that are merely associated with it. Training and evaluating AI agents to perform this workflow end-to-end is difficult because real world biobanks lack known causal ground truth and participant-level data is access controlled. We introduce DrugTargetWorld, a framework that procedurally generates simulated biobanks, or "worlds," with known but concealed causal structure. Each world contains genotypes, proteins, health records, outcomes, and synthetic magnetic resonance imaging (MRI) for 54,000 participants. Agents must construct a disease phenotype, identify causal driver proteins, infer the beneficial direction of modulation, and optionally conduct virtual 'wet lab' experiments. We evaluated nine agents in 540 episodes across 20 cardiovascular worlds and three experimental budgets. Opus 5 and GPT-5.6 Sol achieved the highest mean composite scores, 39.98 and 35.38 of 100, respectively, and both recovered 64% of causal drivers on average. However, no agent reliably distinguished misleading non-causal proteins, and performance remained limited by the integrative judgments required to connect phenotype construction, causal evidence, and intervention decisions. By making each world's causal structure known to the evaluator but hidden from the agent, DrugTargetWorld turns end-to-end drug target discovery into a scalable training and evaluation problem with verifiable reward.

Comment
34 pages main text, 92 pages supplementary material; 6 main figures. Project: https://DrugTargetWorld.vercel.app. Code: https://github.com/sammargolis/DrugTargetWorld. Data: https://huggingface.co/datasets/sammargolis/DrugTargetWorld-assets

Closest papers

Nearest neighbours by meaning across the whole index.

BioXArena-Pro: a research-grade benchmark for autonomous biomedical machine learning agents

cs.LG ·2026-11-10 ·Loka Li, Duzhen Zhang, Xingbo Du, Leonard Song, Kun Zhang +1 more
benchmarkcode/data similarity 0.66
Abstract · 51 pages (22 main text, 29 supplementary information), 5 figures, 7 supplementary tables. Code: https://github.com/mbzuai-ai4bio/BioXArena-P…

Coding agents are increasingly proposed as autonomous builders of biomedical models, but existing benchmarks are small, near saturation or open to leaked information. We present BioXArena-Pro, 64 research-level modelling tasks from eight biomedical domains, each rebuilt from a published study; most hold out whole biological units such as species or cohorts. Across 22 agent configurations, the best scores 55.1 of 100, and the scaffold matters almost as much as the model. We re-ran a published method for every task: where the published recipe applies unchanged, the best agent and the methods tie; on rebuilt tasks the methods trail by 8.2 points, suggesting that agents gain by adapting to new data. Pretrained models (including biological foundation models) matter where the strongest agent uses them: forbidding them decreases its score on those tasks by 9 points. Every task was audited in several AI-assisted rounds and a final human review.

0.35

DrugHarness: An Evolvable Agent Harness for Computational Drug Discovery

cs.AI ·2026-10-16 ·Yuxing Chen, Zhisheng Zhang, Cheng Tang, Wei Li, Minghui Zhang +18 more
hot direction similarity 0.63
Abstract

Computational drug discovery requires agents to compose scientific operations and adapt to changing evidence and constraints. Here we introduce DrugHarness, an evolvable agent harness coupling composable scientific execution with conditional skill induction. Its environment integrates over 80 scientific operations, biomedical resources and task-specific code, preserving associations among candidates, results and artifacts. From execution trajectories and outcome feedback, DrugHarness induces action hypotheses with observable applicability conditions, recommended actions and supporting evidence. An independent review agent evaluates candidate skills derived from these hypotheses through source verification and, when needed, targeted execution trials. Admitted skills guide subsequent tasks and are revised through feedback. Evaluation on MolBench and SMDD-Bench demonstrates capabilities in molecular screening, optimization and constrained design. Without evolution, DrugHarness exceeds reported MolClaw-CC results by 10.8 percentage points in affinity-comparison accuracy and 55% in mean top-three active hits on MolBench. Retrospective evaluation on skill-development tasks shows that evolution increases Qwen's affinity-comparison accuracy from 62.2% to 81.1% and optimization success from 79.5% to 87.2%. In a prospective HPK1 study, DrugHarness achieves a more favorable median docking score than Biomni among system-specific candidates. A synthesized compound achieves a cellular IC50 of 14.19 nM, a 2.64-fold potency improvement over the best input reference, with activity competitive with two selected compounds designed by experienced medicinal chemists. These results support conditional skill evolution for scientific agents and demonstrate a workflow connecting computational drug design with experimental validation.

0.25

AI-Driven Reproducibility and Analytical Robustness in Scientific Discovery

cs.AI cs.CL ·2026-10-16 ·Shicheng Liu, Krista Opsahl-Ong, Andrew Drozdov, Julian Killingback, Arnav Singhvi +4 more
benchmark similarity 0.62
Abstract

Reproducible and analytically robust research findings are essential to scientific progress, but evaluating these properties typically requires costly manual effort. We investigate whether LLM agents can help automate reproduction and robustness analysis, using a medical case study grounded in the Surveillance, Epidemiology, and End Results (SEER) database, a widely used U.S. cancer registry underlying tens of thousands of published studies. First, we introduce SEER-Repro, a benchmark of 20 published SEER-based papers together with the data and resources required to reproduce their findings. Second, we create an AI agent that successfully reproduces 77.4% of 2,190 atomic claims, while providing executable baselines for further analysis. Third, we develop an agentic analysis pipeline to test the robustness of the medical findings by identifying analytical choices underlying each finding, proposing defensible alternatives, and rerunning the analysis to determine whether those choices affect the conclusion. Across published papers in SEER-Repro, our pipeline identifies potentially consequential analytical choices in 9.5% of fully reproduced findings and flags them for expert review. These results show how LLM agents can support scientific review by reproducing findings, systematically testing their robustness, and directing expert attention toward potentially consequential analytical choices.

0.22

LabAgent: Customize Any Research Hubs for Scientific Discoveries Using AI Agents

cs.AI q-bio.BM ·2026-09-11 ·Lei Liu, Yikun Zhang, Jialin Chen, Wanjia Zhao, Rex Ying +5 more
similarity 0.62
Abstract

Scientific research is a continuous process that emphasizes inheritance. Methods developed by predecessors are often expanded upon by new researchers to explore more novel and in-depth scientific questions. However, the change of lab staff, such as student graduation, leads to a lack of personnel capable of replicating methods. Methods that have been developed with significant effort and resources cannot be continued. To address these limitations, we propose LabAgent, a reproduce and discovery harness tailored for a lab's continuous work. LabAgent employs two mechanisms to guarantee that all skills can be executed and verified and to record the corrective methods and experiences, allowing for direct correction or avoidance of similar errors. We applied LabAgent to drug property prediction, biomedical problem analysis, protein variant effect prediction, and statistical genetics in life science domains. LabAgent ranks first over commercial generalist agents in every domain, and demonstrates accurate reproduction of a published figure. Overall, these results demonstrate that LabAgent can effectively integrate and reasonably expand laboratory knowledge.

0.13

From Given to Gathered Evidence: Agentic Learning for Longitudinal Medical Reasoning

cs.CV ·2026-09-30 ·Minye Shao, Chaohui Yu, Yixuan Wu, Fan Wang, Ling Shao +4 more
benchmarkcode/data similarity 0.61
Abstract · Code: https://github.com/VinyehShaw/CASE ; Hugging Face: https://huggingface.co/CASE-Bench

Foundation models can serve as clinical agents through tool-use harnesses. However, conventional medical benchmarks assess reasoning over preselected evidence rather than the ability to seek it across clinical records and longitudinal imaging. We propose CASE: a series of role-specific Clinical Agents for Seeking Evidence, together with a tool-use harness and an agentic post-training framework for compact vision-language policy models. We further introduce a longitudinal multimodal benchmark built on UK Biobank, comprising 50,401 clinical questions derived from real-world ICD-10-coded diagnoses of 4,739 participants. Each question links to a patient-specific environment containing clinical context and multi-sequence MRI from baseline and follow-up visits, where agents autonomously select which visits, organs, modalities, slices, and specialist tools to inspect and compare. Supervised fine-tuning transfers evidence-seeking workflows from 147,434 frontier-model interaction trajectories, followed by agentic reinforcement learning on the learner's own environment interactions. Privileged on-policy self-distillation and rubric-based LLM feedback refine evidence-to-conclusion reasoning without prescribing tool sequences. Experiments show that CASE moves beyond question-answer imitation toward transferable investigation policies, strengthening evidence-grounded longitudinal reasoning. Under matched evaluation conditions, our Qwen3-VL-8B-Instruct based agent achieves over 16% and 10% relative improvements in answer accuracy over GPT-5.4 and Claude Opus 4.8. Project page available at: https://vinyehshaw.github.io/case-project/.

0.33

Searching for What Matters: Open-Ended Discovery of Multiple Hypotheses with Agentic Data Exploration

cs.LG ·2026-10-13 ·Sanchit Kabra, Nurendra Choudhary, Jiangshu Du, Eddie Huang, Danai Koutra +1 more
benchmark similarity 0.61
Abstract

Discovering what drives an outcome from data is central to science and often requires deciding what is worth investigating before a specific hypothesis is known. Yet most existing hypothesis generation settings substantially narrow this search by providing a research question, target relationship, or curated context. We introduce open-ended multiple hypothesis discovery, where a system receives only a large tabular dataset and an outcome and must discover multiple data-supported hypotheses without knowing in advance the relevant variables, functional forms, conditions, or number of underlying mechanisms. To study this problem, we introduce a benchmark built from structural causal models grounded in real-world data schemas, containing 351 planted hypotheses across 15 tasks and five domains, with 53--65 variables and 1M--10M rows per task. The causal model is hidden from the discovery method and retained only by the evaluator, allowing proposed hypotheses to be tested through interventions and separating observational discovery from causal validation. We further propose HypAgent, which treats the dataset as an interactive environment and performs iterative search by proposing candidate directions, triaging and refining promising hypotheses, and removing explained signal so that each accepted discovery redirects subsequent search. HypAgent achieves 0.47 precision, 0.51 recall, and 0.49 F1, compared with 0.35 F1 for the strongest baseline. Our analysis shows that many failures occur after a relevant variable has already been surfaced, suggesting that correctly characterizing a mechanism's functional form and conditions, rather than merely identifying relevant variables, remains a key challenge in open-ended discovery.

0.13

Proximal Causal Learning under Unmeasured Confounding

cs.LG ·2026-10-03 ·Ying Tang, Yi Wang
similarity 0.61
Abstract · 14 pages,4 figures

Estimating treatment effects from observational data typically relies on the No Unmeasured Confounding Assumption (NUCA), which rarely holds in practice. Proximal causal learning (PCL) addresses unmeasured confounding via proxy variables, yet existing methods require the proxy variables to be pre-specified. Thus, we propose PCL-U, a framework that learns proxy variables directly from observed covariates. PCL-U uses neural encoders to decompose covariates into treatment-inducing, outcome-inducing, and shared proxies, guided by minimax mutual information objectives, and obtains causal estimates through a practical moment-based risk function. Experiments on benchmarks show that PCL-U matches or outperforms existing baselines. Besides, there are two types of synthetic datasets with varying dimensions and confounding strengths that illustrate that our method maintains stable estimation accuracy.

0.14

CausalArena: Benchmarking Causal Discovery in the Foundation Model Era

cs.LG ·2026-09-10 ·Zi-Rong Li, Si-Yang Liu, Tian-Zuo Wang, Han-Jia Ye
benchmark similarity 0.61
Abstract · 47 pages, 19 figures

Causal discovery aims to uncover causal structures from data and is fundamental to scientific reasoning and intervention-based decision making. Its evaluation relies heavily on structural causal models (SCMs), which specify a causal graph together with the mechanisms that generate data, yet existing studies differ substantially in graph families, mechanisms, and evaluation protocols. The emergence of causal discovery foundation models (CDFMs) further complicates evaluation: performance may reflect not only causal discovery ability, but also overlap between pretraining environments and test SCMs, making results on fixed synthetic benchmarks difficult to interpret. We introduce CausalArena, a unified and evolvable benchmark for causal discovery under a common protocol. Synthetic SCMs supply controlled breadth over structures and mechanisms; semantic operational SCMs provide human-auditable, semantically grounded environments beyond standard synthetic generators; and formula-grounded SCMs test discovery under explicit scientific mechanisms. Public real-world datasets provide an additional external-validity check. Experiments across classical, neural, and pretrained methods reveal substantial ranking shifts across SCM families and protocols, showing that strong performance in one benchmark regime does not reliably transfer to others. These results highlight benchmark diversity and pretraining--evaluation overlap as central challenges for evaluating causal discovery in the foundation model era.

0.29